SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Timely ReAuthoriza-
tion of Necessary Stem-cell Programs Lends Access to 
Needed Therapies Act of 2021’’ or the ‘‘TRANSPLANT 
Act of 2021’’. 
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 
TRANSPLANTATION PROGRAM. 
(a) ADVISORY COUNCIL MEETINGS.—Subsection (a) 
of section 379 of the Public Health Service Act (42 U.S.C. 
274k) is amended by adding at the end the following new 
paragraph: 
‘‘(7) The Secretary shall convene the Advisory 
Council at least two times each calendar year.’’. 
(b) INCREASING COLLECTION.— 
(1) TECHNICAL CLARIFICATION.—Effective as 
if included in the enactment of Public Law 114–104 
(the Stem Cell Therapeutic and Research Reauthor-
ization Act of 2015), the amendment to section 
379(d)(2)(B) of the Public Health Service Act (42 
U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public 
Law 114–104 is amended by inserting ‘‘goal of in-
creasing collections of high quality’’ before ‘‘cord 
blood units,’’. 
(2) ELIMINATING
DEADWOOD.—Subparagraph 
(B) of section 379(d)(2) of the Public Health Serv-
ice Act (42 U.S.C. 274k(d)(2)) is amended by strik-
ing the second and third sentences in such subpara-
graph. 
(c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec-
tion 379 of the Public Health Service Act (42 U.S.C. 
274k) is amended by adding at the end the following new 
subsection: 
‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 
‘‘(1) REVIEW.—Not less frequently than every 
2 years, the Secretary, in consultation with the Di-
rector of the National Institutes of Health, the Com-
missioner of Food and Drugs, the Administrator of 
the Health Resources and Services Administration, 
the Advisory Council, and other stakeholders, where 
appropriate given relevant expertise, shall conduct a 
review of the state of the science of using adult stem 
cells and birthing tissues to develop new types of 
therapies for patients, for the purpose of considering 
the potential inclusion of such new types of therapies 
in the Program. 
‘‘(2) 
RECOMMENDATIONS.—Not 
later 
than 
June 30, 2025, the Secretary shall— 
‘‘(A) complete the second review required 
by paragraph (1); and 
‘‘(B) informed by such review, submit to 
the Committee on Health, Education, Labor,
and Pensions of the Senate and the Committee 
on Energy and Commerce of the House of Rep-
resentatives recommendations on the appro-
priateness of the inclusion of new types of 
therapies in the Program.’’. 
(d) AUTHORIZATION OF APPROPRIATIONS.—Section 
379B of the Public Health Service Act (42 U.S.C. 274m) 
is amended by striking ‘‘$33,000,000 for fiscal year 2015 
and $30,000,000 for each of fiscal years 2016 through 
2020’’ and inserting ‘‘$31,009,000 for each of fiscal years 
2022 through 2026’’. 
SEC. 3. CORD BLOOD INVENTORY. 
Subsection (g) of section 2 of the Stem Cell Thera-
peutic and Research Act of 2005 (42 U.S.C. 274k note) 
is amended to read as follows: 
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there is authorized to be appro-
priated $23,000,000 for each of fiscal years 2022 through 
2026.’’. 
SEC. 4. ADVANCING THE FIELD OF REGENERATIVE MEDI-
CINE. 
Section 402 of the Public Health Service Act (42 
U.S.C. 282) is amended by adding at the end the fol-
lowing:
‘‘(o) REGENERATIVE MEDICINE.—The Director of 
NIH shall, as appropriate, continue to consult with the 
directors of relevant institutes and centers of the National 
Institutes of Health, other relevant experts from such in-
stitutes and centers, and relevant experts within the Food 
and Drug Administration, to further the field of regenera-
tive medicine using adult stem cells, including autologous 
stem cells, therapeutic tissue engineering products, human 
cell and tissue products, human gene therapies, and ge-
netically modified cells.’’. 
SEC. 5. GAO REPORT ON REGENERATIVE MEDICINE WORK-
FORCE. 
Not later than 2 years after the date of enactment 
of this Act, the Comptroller General of the United States 
shall submit to the Committee on Health, Education, 
Labor, and Pensions of the Senate and the Committee on 
Energy and Commerce of the House of Representatives 
a report that assesses a specialized health care workforce 
in the field of regenerative medicine. The report shall in-
clude— 
(1) an overview of the current employment lev-
els, in both commercial and academic settings, for— 
(A) positions necessary for the collection 
and transplantation of stem cell therapeutics, 
including bone marrow and cord blood; and
(B) positions in the field of regenerative 
medicine using adult stem cells and related to 
product development; 
(2) the identification of gaps, if any, in the pro-
jected workforce capacity for— 
(A) positions described in paragraph 
(1)(A); and 
(B) the field of regenerative medicine using 
adult stem cells, including workforce gaps re-
lated to the development of new cellular thera-
pies using adult stem cells; 
(3) an overview of the availability of training 
programs related to the development, refinement, 
and utilization of adult stem cells, including training 
on good manufacturing practices for such activities, 
and the performance of such programs; and 
(4) recommendations, if any, for improving the 
workforce capacity related to— 
(A) the positions described in paragraph 
(1)(A); or